HN Hodis, WJ Mack, L Zheng, Y Li, M Torres, D … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Overall, average rates of CCA-IMT change were not significantly different between
troglitazone- and placebo-treated subjects (0.0030 ± 0.021 vs. 0.0066 ± 0.021 mm/year; P =
0.17). In the stratum of subjects with CCA-IMT ≥0.8 mm, troglitazone significantly ... Cited by 24 - Related articles - BL Direct - All 5 versions
T Mazzone - Current opinion in cardiology, 2005 - journals.lww.com Recent findings: Appropriate management of hypertension and hyperlipidemia has been shown
unequivocally to reduce cardiovascular events. Benefit has been demonstrated with multiple
antihypertensive agents; however, some studies suggest an advantage for angiotensin- ... Cited by 8 - Related articles - BL Direct - All 5 versions
ES Rosmarakis, ME Falagas - American Heart Journal, 2007 - Elsevier Five RCTs that included 235 evaluable patients who underwent coronary stent implantation and
received a 6-month pioglitazone or rosiglitazone therapy were included in our
meta-analysis. Restenosis rate was significantly lower in patients who received ... Cited by 21 - Related articles - All 39 versions
ZH Wang, F Luo, XM Liu - Yao xue xue bao= Acta pharmaceutica …, 2005 - ncbi.nlm.nih.gov AIM: To explore the prevention of atherosclerosis by PPARy agonist rosiglitazone.
METHODS: 24 male New Zealand white rabbits weighing 1.8 to 2.2 kg were randomly divided
into 3 groups: control group, normal rabbit chow; cholesterol group, 1% cholesterol diet; ... Cited by 6 - Related articles - BL Direct
DJ Stocker, AJ Taylor, RW Langley, MR Jezior, RA … - American heart journal, 2007 - Elsevier Metformin and rosiglitazone treatment led to similar significant improvements in glycemic control
(HbA 1c −1.08% in the rosiglitazone group and −1.18% in the metformin group, P =
nonsignificant). High-sensitivity C-reactive protein levels decreased by an average of ... Cited by 48 - Related articles - All 9 versions
T Mazzone - The American journal of cardiology, 2004 - Elsevier Diabetes mellitus and impaired glucose tolerance (IGT) are common disorders, and their prevalence
is predicted to increase over the next several decades. The major serious complication of these
disorders is large vessel atherosclerosis leading to myocardial infarction and stroke. ... Cited by 30 - Related articles - All 6 versions
DM Riche, R Valderrama, NN Henyan - Diabetes Care, 2007 - Am Diabetes Assoc OBJECTIVE—Thiazolidinediones (TZDs) (rosiglitazone and pioglitazone) are a class of antidiabetes
agents that have a high affinity for peroxisome proliferator–activated receptor-γ. TZDs initiate
a multitude of physiologic processes that may elicit benefits as systemic agents for the ... Cited by 26 - Related articles - All 6 versions
F Neto, O Ribeiro, DB Precoma, A Alessi, C … - Thrombosis …, 2008 - thrombosisjournal.com There was no significant difference in intima/media layer area ratio between the control group
and the rosiglitazone group. Rosiglitazone did not reduce the probability of lesions types I, II,
or III (72.73% vs. 92.31%; p = 0.30) and types IV or V (27.27% vs. 7.69%; p = 0.30). There ... Cited by 2 - Related articles - Cached - All 7 versions
- ►darkmay.cz [PDF] F Blaschke, R Spanheimer, M Khan, RE Law - Vascular pharmacology, 2006 - Elsevier The incidence of diabetes, now affecting more than 170 million individuals is growing
rapidly. Type 2 diabetes, which accounts for 90% of all diabetes cases, is associated with increased
cardiovascular morbidity and mortality. Thiazolidinediones (TZDs), used for the treatment ... Cited by 40 - Related articles - All 5 versions
S Bernard, A Sérusclat, F Targe, S Charrière, O … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS —Age, carotid IMT, carotid plaques, number of risk factors, Framingham score, and
suboptimal exercise electrocardiogram were associated with incident cardiovascular events
(P < 0.05). Carotid IMT was an independent predictor of cardiovascular events (P = ... Cited by 43 - Related articles - All 5 versions
